Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Journal of the American Academy of Dermatology

Volumn 66, Issue 5, 2012, Pages 742-751

  Gordon, Kenneth B ^a   Papp, Kim A ^b   Langley, Richard G ^c   Ho, Vincent ^d   Kimball, Alexa B ^e   Guzzo, Cynthia ^f   Yeilding, Newman ^f   Szapary, Philippe O ^f   Fakharzadeh, Steven ^f   Li, Shu ^f   Hsu, Ming Chun ^f   Reich, Kristian ^g  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CENTOCOR INC   (United States)

^g Dermatologikum Hamburg   (Germany)

Author keywords

malignancy; nonmelanoma skin cancer; psoriasis; safety; serious infection; ustekinumab

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; USTEKINUMAB;

ARTICLE; CANCER EPIDEMIOLOGY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INFECTION; INFECTION RATE; PRIORITY JOURNAL; PSORIASIS; SKIN CANCER;

ADULT; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFECTION; LONG-TERM CARE; MALE; MIDDLE AGED; NEOPLASMS; PSORIASIS; RISK ASSESSMENT; SAFETY MANAGEMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859869815     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.06.041     Document Type: Article

References (29)

1. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-9. (Pubitemid 47374611)
2. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther 2009;22:431-40.
3. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92. (Pubitemid 46220818)
4. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al; PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74.
5. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al; PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84.
6. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
7. Lebwohl M, Leonardi C, Griffiths CEM, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from pooled analyses of phase 2 and 3 clinical trials through up to 3 years. J Am Acad Dermatol doi: 10.1016/j.jaad.2011.06.011. Published online September 20, 2011.
8. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4. (Pubitemid 37490789)
9. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5. (Pubitemid 44264796)
10. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9. (Pubitemid 46764070)
11. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
12. Tsai T-F, Ho J-C, Song M, Szapary P, Guzzo C, Shen Y-K, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011;63:154-63.
13. Frazer JK, Capra JD. Immunoglobulins: structure and function. In: Paul WE, editor. Fundamental immunology. 4th ed. Philadelphia: Lippincott-Raven; 1999. pp. 37-74.
14. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
15. Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol doi: 10.1016/j.jaad.2010.07.026. Published online September 20, 2010.
16. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353:2262-9. (Pubitemid 41697289)
17. Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 2006;19:245-52. (Pubitemid 43740362)
18. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68.
19. Novelli F, Casanova JL. The role of IL-12, IL-23 and IFN-γ in immunity to viruses. Cytokine Growth Factor Rev 2004;15:367-77. (Pubitemid 39140700)
20. Fieschi C, Casanova JL. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol 2003;33:1461-4. (Pubitemid 36790405)
21. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010;89:381-402.
22. Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010;9:928-37.
23. Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol 2008;7:1137-46.
24. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68. (Pubitemid 34229390)
25. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A 2007;104:3996-4001. (Pubitemid 47181567)
26. Liu L, Shan B, Feng Y. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell Immunol 2009;258:181-7.
27. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003;171:600-7. (Pubitemid 36871367)
28. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007;178:7571-80. (Pubitemid 46898026)
29. Cárdenes M, Angel-Moreno A, Fieschi C, Sologuren I, Colino E, Molinés A, et al. Oesophageal squamous cell carcinoma in a young adult with IL-12R beta 1 deficiency. J Med Genet 2010;47:635-7.